Prentiss Smith & Co’s AstraZeneca AZN Stock Holding History

Prentiss Smith & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-723	Closed	-$45K	–	250
2017 Q1	$45K	Hold	723	–	–	0.03%	120
2016 Q4	$40K	Hold	723	–	–	0.02%	129
2016 Q3	$48K	Hold	723	–	–	0.03%	124
2016 Q2	$44K	Hold	723	–	–	0.02%	127
2016 Q1	$41K	Hold	723	–	–	0.02%	139
2015 Q4	$49K	Buy	+723	New	+$47.4K	0.03%	126

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Prentiss Smith & Co's AZN Position: Q2 2017 in Review

Prentiss Smith & Co sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 723 shares — an estimated $45K sold.

Prentiss Smith & Co first reported a position in AZN in Q4 2015 and held it in 6 quarters. The position peaked at $49K in Q4 2015. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

Prentiss Smith & Co reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
Prentiss Smith & Co sold 723 AstraZeneca shares in Q2 2017, an estimated $45K.
Prentiss Smith & Co first reported a position in AstraZeneca in Q4 2015 and held it in 6 quarters.
Prentiss Smith & Co's AstraZeneca position peaked at $49K in Q4 2015.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Prentiss Smith & Co's 13F filing for Q2 2017, filed 10 Jul 2017.